PTP1B antisense-treated mice show regulation of genes involved in lipogenesis in liver and fat

JF Waring, R Ciurlionis, JE Clampit, S Morgan… - Molecular and cellular …, 2003 - Elsevier
JF Waring, R Ciurlionis, JE Clampit, S Morgan, RJ Gum, RA Jolly, P Kroeger, L Frost…
Molecular and cellular endocrinology, 2003Elsevier
Protein tyrosine phosphatases are important regulators of insulin signal transduction. Our
studies have shown that in insulin resistant and diabetic ob/ob and db/db mice, reducing the
levels of protein tyrosine phosphatase 1B (PTP1B) protein by treatment with a PTP1B
antisense oligonucleotide resulted in improved insulin sensitivity and normalized plasma
glucose levels. The mechanism by which PTP1B inhibition improves insulin sensitivity is not
fully understood. We have used microarray analysis to compare gene expression changes …
Protein tyrosine phosphatases are important regulators of insulin signal transduction. Our studies have shown that in insulin resistant and diabetic ob/ob and db/db mice, reducing the levels of protein tyrosine phosphatase 1B (PTP1B) protein by treatment with a PTP1B antisense oligonucleotide resulted in improved insulin sensitivity and normalized plasma glucose levels. The mechanism by which PTP1B inhibition improves insulin sensitivity is not fully understood. We have used microarray analysis to compare gene expression changes in adipose tissue, liver and muscle of PTP1B antisense-treated ob/ob mice. Our results show that treatment with PTP1B antisense resulted in the downregulation of genes involved in lipogenesis in both fat and liver, and a downregulation of genes involved in adipocyte differentiation in fat, suggesting that PTP1B antisense acts through a different mechanism than thiazolidinedione (TZD) treatment. In summary, microarray results suggest that reduction of PTP1B may alleviate hyperglycemia and enhance insulin sensitivity by a different mechanism than TZD treatment.
Elsevier